Cannabis use and risk of schizophrenia: A Mendelian randomization study

Molecular Psychiatry

Volumn 23, Issue 5, 2018, Pages 1287-1292

  Vaucher, J ^a   Keating, B J ^b   Lasserre, A M ^a   Gan, W ^c,d   Lyall, D M ^e   Ward, J ^e   Smith, D J ^e   Pell, J P ^e   Sattar, N ^e   Pare G ^f,g,h,i   Holmes, M V ^c,j  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f MCMASTER UNIVERSITY   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j MEDICAL RESEARCH COUNCIL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANNABIS USE; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; MENDELIAN RANDOMIZATION ANALYSIS; MENTAL HEALTH; OBSERVATIONAL STUDY; PLEIOTROPY; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ADULT; CANNABIS ADDICTION; CANNABIS SMOKING; CASE CONTROL STUDY; CAUCASIAN; FEMALE; GENETIC VARIATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PSYCHOLOGY; RANDOMIZATION;

CANNABIS;

ADULT; CANNABIS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOM ALLOCATION; RISK FACTORS; SCHIZOPHRENIA; SMOKERS;

EID: 85010886820     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.252     Document Type: Article

References (34)

1. United Nations Office on Drugs and Crime. World Drug Report 2015 (United Nations publication, Sales No. E.15.XI.6). Available at http://www.unodc.org/ documents/wdr2015/World-Drug-Report-2015.pdf. Accessed 16. May 2016.
2. Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 2016; 79: 549-556.
3. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016; 14: 1121-1126.
4. McEvoy JP. The costs of schizophrenia. J Clin Psychiatry 2007; 14: 4-7.
5. Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Buxton J et al. Public health and international drug policy. Lancet 2016; 387: 1427-1480.
6. Sherif M, Radhakrishnan R, D'Souza DC, Ranganathan M. Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry 2016; 79: 526-538.
7. Large M, Di Forti M, Murray R. Cannabis: debated schizophrenia link. Nature 2015; 527: 305.
8. Rabin RA, George TP. A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am J Addict 2015; 24: 105-116.
9. Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where are we now and where are we going? Int J Epidemiol 2015; 44: 379-388.
10. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37: 658-665.
11. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44: 512-525.
12. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-314.
13. Burgess S, Dudbridge F, Thompson SG. Re: "Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects". Am J Epidemiol 2015; 181: 290-291.
14. Stringer S, Minica CC, Verweij KJ, Mbarek H, Bernard M, Derringer J et al. Genomewide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. Transl Psychiatry 2016; 29: 36.
15. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-328.
16. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199.
17. Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 1990; 178: 473-480.
18. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156: 319-327.
19. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-1213.
20. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330: 11.
21. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res; e-pub ahead of print 17. August 2015; pii: 096228021559757.
22. Thomas DC, Lawlor DA, Thompson JR. Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. Ann Epidemiol 2007; 17: 511-513.
23. Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Pare G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J 2015; 36: 1454-1462.
24. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol 2016; 40: 597-608.
25. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol; e-pub ahead of print 11. September 2016; pii: dyw220.
26. Corbin LJ, Richmond RC, Wade KH, Burgess S, Bowden J, Smith GD et al. BMI as a modifiable risk factor for type 2 diabetes: refining and understanding causal estimates using mendelian randomization. Diabetes 2016; 65: 3002-3007.
27. Gelernter J, Kranzler HR, Sherva R, Koesterer R, Almasy L, Zhao H et al. Genomewide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry 2014; 76: 66-74.
28. Yang BZ, Kranzler HR, Zhao H, Gruen JR, Luo X, Gelernter J. Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. Alcohol Clin Exp Res 2008; 32: 2117-2127.
29. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014; 349: g4164.
30. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315-2381.
31. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103: 9-15.
32. French L, Gray C, Leonard G, Perron M, Pike GB, Richer L et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry 2015; 72: 1002-1011.
33. Gage SH, Hickman M, Heron J, Munafo MR, Lewis G, Macleod J et al. Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children. Psychol Med 2014; 44: 3435-3444.
34. Dekker N, Meijer J, Koeter M, van den Brink W, van Beveren N, Kahn RS et al. Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychol Med 2012; 42: 1903-1911.